Arvinas Inc

Arvinas’s FDA approval of VEPPANU (vepdegestrant) marks the first protein‑degradation drug in oncology, promising rapid growth in ER+ breast cancer treatment and strong upside for investors.

Arvinas Inc. gears up for a Q4 2025 earnings report, engaging investors via conferences and positioning itself in the $4.53 bn targeted protein degradation market poised for 32% CAGR growth to 2033.

Arvinas Inc. is undergoing a strategic pivot after Pfizer pulls back on commercializing its PROTAC inhibitor, leading to layoffs, a share buyback program, and a reorientation of the company’s operational strategy.

Arvinas Inc. is struggling financially despite scientific progress, leading to leadership changes and strategic shifts in an effort to turn the company’s fortunes around.

Arvinas Inc. is facing significant challenges, including stock rating downgrades, workforce reductions, and trial cancellations, amidst a strategic shift in its cancer drug development and financial performance.